- Volume 5
- Issue 3 Publication Date: December 2006
Phase II Study of Low-Dose Docetaxel/ Estramustine in Elderly Patients or Patients Aged 18-74 Years with Hormone-Refractory Prostate Cancer
Sreeni Chittoor, William Berry, David Loesch, Keith Logie, John Fleagle, Stephanie Mull, Kristi A. Boehm, Feng Zhan, Lina Asmar
Purpose: Chemotherapy is often poorly tolerated in elderly patients or patients with poor performance status. This trial was designed to determine whether low-dose weekly docetaxel/estramustine was efficacious with acceptable toxicity. Patients and Methods: Dexamethasone was administered as premedication. Subjects received docetaxel 25 mg/m2 intravenously on days 2, 9, and 16 and estramustine 140 mg orally twice daily on days 1-3, 8-10, and 15-17. Cycles were 28 days. Participants received ≤ 6 cycles unless progression or intolerable toxicity occurred. Results: Fifty-eight subjects were enrolled at 31 sites in the US Oncology Network. Median age was 78 years (range, 64-92 years); performance status scores (0, 1, 2, and 3) were 36%, 38%, 24%, and 2%, respectively; 55 subjects received ≥ 1 cycle of treatment; and 4 participants were nonevaluable because they completed‹2 cycles. Among the 56 treated subjects, 38 (68%) had a decreased prostate-specific antigen level ( ≥ 50% compared with baseline level and maintained for ≥ 4 weeks). There were 40 subjects with measurable tumor(s). Responses, assessed using Response Evaluation Criteria in Solid Tumors, were 1 complete response (2.5%), 7 partial responses (17.5%), 26 stable diseases (65%), and 6 progressive diseases (15%). At 1 year, 17% of participants were progression free; median progression-free survival was 5.3 months (range, 1-14.5 months); estimated 1-year survival was 65%. There were no grade 4 treatment-related events. Grade 3 treatment-related events included fatigue/asthenia (11%) and arrhythmia, dehydration, cerebral ischemia, thrombocytopenia, and dyspnea (4% each). There was 1 treatment-related death (acute respiratory distress syndrome). Conclusion: These findings suggest that elderly men with advanced-stage prostate cancer tolerate this regimen, with significant responses and prolonged progression-free survival. These patients should not be excluded from chemotherapeutic interventions based on age alone.